 Shares of the U.S.-listed Chinese immuno-oncology company I-Mab NASDAQ: IMAB offer strong upside potential, according to a Needham analyst. The I-Mab Analyst: Chad Messer initiated coverage of I-Mab shares with a Buy rating and 75 price target. 